“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
Welcome to POLITICO’s new Global Public Health Spotlight, an extension of the Global Translations newsletter. Every week, we take care of the main ones facing the world. Register here.
At the beginning of the coronavirus pandemic, existing drugs were expected to help cure others inflamed with the new virus.
But six months and some false beginnings later, hopes have faded. There have only been a handful of drugs approved or since the World Health Organization (WHO) declared the coronavirus outbreak a pandemic in March, basically to treat other people hospitalized with Covid-19 severe, a disease caused by the virus.
“We now have very few teams that have proven effective,” Mariangela Simao, WHO Deputy Director-General for Access to Medicines, Vaccines and Pharmaceuticals, said this week.
However, it hopes that some of the many large-scale tests being conducted on possible treatments will bring news until the end of the year.
According to Policy Cures Research, a group of global fitness experts, researchers are conducting trials on about 330 drugs, 150 of which are already being tested on people. Of these, nearly 60 are in the last stages of testing.
The promise and disadvantages of biotherapies
Policy Cures Research CEO Nick Chapman told POLITICO that in the maximum positive scenario, some of the so-called monoclonal antibodies, which can prevent others from contracting Covid-19 and treating the disease, can be approved through the end of the year.
The U. S. National Institutes of Health But it’s not the first time They describe these antibodies as laboratory-manufactured versions of naturally produced proteins through the immune formula in reaction to invasive viruses or other pathogens. serve as part of covid-19’s pandemic reaction until vaccines become available,” the NIH said.
Eli Lilly drug brands; Regeneron and Roche; and CSL Behring and Takeda are some of those that are running in such therapies, according to Chapman and the International Federation of Pharmaceutical Associations and Manufacturers (IFPMA).
There are about 70 in progression for the remedy and prevention of Covid-19, according to the clinical non-profit organization IAVI, which have already been used to treat other types of cancer and autoimmune diseases, with more than one hundred recorded in the afterlife. 30 years, according to a report published in August through IAVI and the Wellcome Global Health Foundation.
These so-called biotherapies are the ultimate promising elegance of drugs that attack the virus, Chapman said, but they also have drawbacks.
Most of them are injectable, which poses disorders even to control them; other people don’t like to get vaccinated, SAID SIMao of WHO.
Increasing production to manufacture millions of doses of biotherapies will also be a major challenge, as the capacity of this production is limited in the world to come, WHO Chief Scientist Soumya Swaminathan said this week.
Finally, they are much more expensive than normal drugs, Chapman said, which can particularly restrict their potential impact.
Hopes fulfilled and disappointed
“Chances are there will be effective treatment for singles, there will be no quick solution to fighting and involving covid-19,” IFPMA CEO Thomas Cueni told reporters in early September.
“We will want other remedies for other patient teams for other stages of the disease,” he said.
In addition to antibody therapies, the industry also uses antivirals and anti-inflammatory drugs to treat others with Covid-19, according to Cueni.
Gilead’s re-employment, which was granted emergency use authorization from the U. S. Food and Drug Administration, was a U. S. food and drug administration. But it’s not the first time In the spring and conditional marketing of the European Medicines Agency this summer, it is in the category of antivirals. A giant study through NIH has shown that it is seriously helping sick people hospitalized others more quickly. Earlier this month, the FDA legalized its use in other teams of less ill hospitalized patients. But it is not yet known whether this prevents deaths.
Gilead CEO Daniel O’Day said the drug is still being tested in some 36 clinical trials and, among other things, they are looking to assess whether it works in the most productive way to fight coronavirus in combination with other drugs, in a cocktail similar to that of drugs. combined to treat people with HIV, for example. The company also tests whether the drug works when inhaled rather than injected, as is the case lately, to make it less difficult to administer.
However, remdesivir would not function as a pill, because of the way it is metabolized in the body, he said. Gilead has so far not met global demand for medicines, but expects it to do so in October. O’Day said.
Chapman, of Policy Cures Research, said it was vital to expand a form of coronavirus remedy tablet to make widespread use.
An experimental drug EIDD-2801, which is being developed through Ridgeback Biotherapeutics and Merck.
In early September, WHO used so-called corticosteroids to treat inflammation caused by coronavirus in others in a severe or critical state, such as dexamethasone, which has been shown to be effective in others receiving respiratory assistance. They have long been used to treat other situations such as asthma, allergies, lupus and rheumatoid arthritis.
Politicians have generated high hopes for remedies to combat coronavirus, but some of the remedies have also been the biggest crises. The top celebrity: hydroxychloroquine, a drug that has been heavily touted through U. S. President Donald Trump, among others.
The FDA granted hydroxychloroquine an emergency use authorization to remove it a few months later, after a clinical trial in hospitalized patients showed that the drug had no advantages in reducing the likelihood of death or accelerating recovery. to serious fitness disorders such as central rhythm disorders and blood disorders, the FDA warned.
In Japan, outgoing Prime Minister Shinzo Abe opted for a drug sold under the Avigan logo to treat the flu. Evidence of Avigan’s effects on coronavirus is expected to end this month in Japan, according to media reports, a may interim report is not promising.
Cueni, of global drug foyer IFPMA, said the industry has come a long way since the start of the pandemic, “but we will have to honestly admit that some hopes have been thwarted. Some hopes have been fulfilled and there is more hope. “to come, ” he said.
What is needed is a transformative treatment to fight the virus, Chapman said of Policy Cures Research. This will take place later than other people expected, ” he said.
Fixing existing drugs as a possible cure for the virus, which most promising drugs in the early stages of development, “has pushed things back,” he said.
LAST COVID VACCINE RACE
AstraZeneca Vaccine Trial Pause: Just as the United States was involved in Trump rushing to find a vaccine that had not yet been proven and effective, it was suspected that testing one of the most complex candidate vaccines had ended due to type concerns. AstraZeneca CEO Pascal Soriot said Thursday that the pause was not uncommon in such trials, but did not check media reports that the player was suffering from transverse myelitis. inflammatory disease that affects the spinal cord. If the company can resume testing soon, it deserves to know before the end of the year whether the vaccine is working to protect others from coronavirus infection, he said.
Vaccines will need to be more than effective in combating the pandemic well: of the top 8 candidate vaccines, only one, produced through CanSino in China, requires a dose for a full vaccination, Policy Cures Research says in a new analysis. And at least 3 of them, those who evolved through Moderna; Pfizer / BioNTech; and AstraZeneca and oxford University: do not meet WHO’s minimum product and garage stability criteria, according to the analysis. The expert group cautions that “to have a broader effect on public fitness and to mitigate the COVID-19 pandemic well, an adequate vaccine will be required in a variety of settings, adding resource-constrained environments and other teams of people. “.
Confidence in vaccines before the pandemic: mistrust and absolute opposition to vaccination have long been a problem, and the ongoing debate about a long-term coronavirus vaccine can make issues worse. A new report released Thursday shows where world-trusted vaccines are located just before the virus. took over.
Between November 2015 and December 2019, “confidence in the importance, protection and efficacy of vaccines has diminished in Afghanistan, Indonesia, Pakistan, the Philippines and South Korea,” says the report, led by Professor Heidi Larson of the Department of Infectious Diseases. Epidemiology of diseases at the London School of Hygiene
OVERVIEW OF GLOBAL HEALTH
North America: Excerpts from a February interview with veteran journalist Bob Woodward determined the country’s news cycle because the president of the United States admitted that he was minimizing the virus knowing it was more fatal than the flu. Anything else Trump has said and resisted in recent months: that the virus is suspended in the air and therefore not only transmits contact between an inflamed user and a fit user.
Latin America: Robot relieves loneliness in Mexican with coronavirus.
Asia: India recorded a record new peak of about 95,000 cases of coronavirus infection in one day. The country surpassed Brazil, the world’s largest moment, after the United States, in terms of number of cases: about 4. 4 million in September. 10.
Europe: Teachers from a Bosnian village build an outdoor classroom for young people in Covid-19.
Middle East: Community transmission of coronavirus occurs in war-torn Syria, according to the UN.
Africa: Nigerian resident doctors have called off their strike to allow the government to meet its demands for higher wages and run amid the pandemic.
Oceania: New Zealanders have experienced more depression and anxiety since the coronavirus was locked up, the country is thought to be a tale of good fortune in the global fight against the pandemic.
Global: Covid-19 can be right in the face of decades of progress towards eliminating preventable child deaths, UN agencies warn.